BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 17182662)

  • 1. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer.
    Zlobec I; Steele R; Terracciano L; Jass JR; Lugli A
    J Clin Pathol; 2007 Oct; 60(10):1112-6. PubMed ID: 17182662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer.
    Zlobec I; Terracciano L; Tornillo L; Günthert U; Vuong T; Jass JR; Lugli A
    Gut; 2008 Oct; 57(10):1413-9. PubMed ID: 18436576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair status.
    Lugli A; Zlobec I; Baker K; Minoo P; Tornillo L; Terracciano L; Jass JR
    J Clin Pathol; 2007 May; 60(5):534-9. PubMed ID: 16816167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Node-negative colorectal cancer at high risk of distant metastasis identified by combined analysis of lymph node status, vascular invasion, and Raf-1 kinase inhibitor protein expression.
    Zlobec I; Baker K; Minoo P; Jass JR; Terracciano L; Lugli A
    Clin Cancer Res; 2008 Jan; 14(1):143-8. PubMed ID: 18172264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer.
    Minoo P; Baker K; Baumhoer D; Terracciano L; Lugli A; Zlobec I
    Hum Pathol; 2010 Jan; 41(1):70-8. PubMed ID: 19740518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic assessment of protein phenotypes characterizing high-grade tumour budding in mismatch repair-proficient colorectal cancer.
    Karamitopoulou E; Lugli A; Panayiotides I; Karakitsos P; Peros G; Rallis G; Patsouris ES; Terracciano L; Zlobec I
    Histopathology; 2010 Aug; 57(2):233-43. PubMed ID: 20716165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New time-dependent approach to analyse the prognostic significance of immunohistochemical biomarkers in colon cancer and diffuse large B-cell lymphoma.
    Adams H; Tzankov A; Lugli A; Zlobec I
    J Clin Pathol; 2009 Nov; 62(11):986-97. PubMed ID: 18977805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer.
    Zlobec I; Günthert U; Tornillo L; Iezzi G; Baumhoer D; Terracciano L; Lugli A
    Histopathology; 2009 Nov; 55(5):564-75. PubMed ID: 19912362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy.
    Zlobec I; Vuong T; Hayashi S; Haegert D; Tornillo L; Terracciano L; Lugli A; Jass J
    Br J Cancer; 2007 Mar; 96(5):793-800. PubMed ID: 17311026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer.
    Zlobec I; Minoo P; Baumhoer D; Baker K; Terracciano L; Jass JR; Lugli A
    Cancer; 2008 Feb; 112(3):495-502. PubMed ID: 18076013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer.
    Karamitopoulou E; Zlobec I; Panayiotides I; Patsouris ES; Peros G; Rallis G; Lapas C; Karakitsos P; Terracciano LM; Lugli A
    Hum Pathol; 2011 Dec; 42(12):1888-96. PubMed ID: 21664646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients.
    Lugli A; Vlajnic T; Giger O; Karamitopoulou E; Patsouris ES; Peros G; Terracciano LM; Zlobec I
    Hum Pathol; 2011 Dec; 42(12):1833-40. PubMed ID: 21664647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer.
    Zlobec I; Minoo P; Baker K; Haegert D; Khetani K; Tornillo L; Terracciano L; Jass JR; Lugli A
    Eur J Cancer; 2007 Apr; 43(6):1101-7. PubMed ID: 17350821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status.
    Kevans D; Wang LM; Sheahan K; Hyland J; O'Donoghue D; Mulcahy H; O'Sullivan J
    Int J Surg Pathol; 2011 Dec; 19(6):751-60. PubMed ID: 21791486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.
    Droeser RA; Hirt C; Viehl CT; Frey DM; Nebiker C; Huber X; Zlobec I; Eppenberger-Castori S; Tzankov A; Rosso R; Zuber M; Muraro MG; Amicarella F; Cremonesi E; Heberer M; Iezzi G; Lugli A; Terracciano L; Sconocchia G; Oertli D; Spagnoli GC; Tornillo L
    Eur J Cancer; 2013 Jun; 49(9):2233-42. PubMed ID: 23478000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new approach to the validation of tissue microarrays.
    Goethals L; Perneel C; Debucquoy A; De Schutter H; Borghys D; Ectors N; Geboes K; McBride WH; Haustermans KM
    J Pathol; 2006 Apr; 208(5):607-14. PubMed ID: 16435284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RHAMM, p21 combined phenotype identifies microsatellite instability-high colorectal cancers with a highly adverse prognosis.
    Zlobec I; Baker K; Terracciano LM; Lugli A
    Clin Cancer Res; 2008 Jun; 14(12):3798-806. PubMed ID: 18559599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the hyaluronan-mediated motility receptor RHAMM in tumor budding cells identifies aggressive colorectal cancers.
    Koelzer VH; Huber B; Mele V; Iezzi G; Trippel M; Karamitopoulou E; Zlobec I; Lugli A
    Hum Pathol; 2015 Nov; 46(11):1573-81. PubMed ID: 26351067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer.
    Minoo P; Zlobec I; Baker K; Tornillo L; Terracciano L; Jass JR; Lugli A
    Am J Clin Pathol; 2007 May; 127(5):820-7. PubMed ID: 17439843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and predictive factors in colorectal cancer.
    Zlobec I; Lugli A
    J Clin Pathol; 2008 May; 61(5):561-9. PubMed ID: 18326017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.